Halo Collective Inc (HCANF)
0.0001
0.00 (0.00%)
USD |
OTCM |
May 31, 16:00
Halo Collective Max Drawdown (5Y): 100.0% for May 31, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
Date | Value |
---|---|
May 31, 2024 | 100.0% |
April 30, 2024 | 100.0% |
March 31, 2024 | 100.0% |
February 29, 2024 | 100.0% |
January 31, 2024 | 100.0% |
December 31, 2023 | 100.0% |
November 30, 2023 | 100.0% |
October 31, 2023 | 100.0% |
September 30, 2023 | 100.0% |
August 31, 2023 | 100.0% |
July 31, 2023 | 100.00% |
June 30, 2023 | 100.00% |
May 31, 2023 | 100.00% |
April 30, 2023 | 100.00% |
March 31, 2023 | 100.00% |
February 28, 2023 | 100.00% |
January 31, 2023 | 100.00% |
December 31, 2022 | 100.00% |
November 30, 2022 | 100.00% |
October 31, 2022 | 100.00% |
September 30, 2022 | 100.00% |
August 31, 2022 | 100.00% |
July 31, 2022 | 100.00% |
June 30, 2022 | 100.00% |
May 31, 2022 | 100.00% |
Date | Value |
---|---|
April 30, 2022 | 100.00% |
March 31, 2022 | 100.00% |
February 28, 2022 | 100.00% |
January 31, 2022 | 100.00% |
December 31, 2021 | 100.00% |
November 30, 2021 | 100.00% |
October 31, 2021 | 100.00% |
September 30, 2021 | 100.00% |
August 31, 2021 | 100.00% |
July 31, 2021 | 100.00% |
June 30, 2021 | 100.00% |
May 31, 2021 | 100.00% |
April 30, 2021 | 100.00% |
March 31, 2021 | 100.00% |
February 28, 2021 | 100.00% |
January 31, 2021 | 100.00% |
December 31, 2020 | 100.00% |
November 30, 2020 | 100.00% |
October 31, 2020 | 100.00% |
September 30, 2020 | 100.00% |
August 31, 2020 | 100.00% |
July 31, 2020 | 100.00% |
June 30, 2020 | 100.00% |
May 31, 2020 | 100.00% |
April 30, 2020 | 100.00% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
100.00%
Minimum
Jun 2019
100.0%
Maximum
Aug 2023
100.00%
Average
100.00%
Median
Jun 2019
Max Drawdown (5Y) Benchmarks
CEN Biotech Inc | -- |
Acasti Pharma Inc | 98.73% |
Aurinia Pharmaceuticals Inc | 87.58% |
Edesa Biotech Inc | 99.58% |
Lexaria Bioscience Corp | 98.90% |